Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer



Status:Completed
Conditions:Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any - 120
Updated:7/20/2017
Start Date:December 2005
End Date:July 2017

Use our guide to learn which trials are right for you!

Molecular Fingerprints in Lung Cancer: Predicting Tumor Response to Therapy

RATIONALE: Studying samples of tumor tissue and blood in the laboratory from patients with
cancer may help doctors learn more about changes that occur in genetic material (DNA and RNA)
and may also identify protein expression patterns related to cancer. It may also help doctors
predict how patients will respond to treatment.

PURPOSE: This research study evaluates changes in DNA, RNA, and proteins with the goal of
predicting response to treatment in patients with lung cancer.

OBJECTIVES:

- To determine protein and/or RNA expression patterns capable of predicting tumor response
to therapy in tumor tissue samples from patients with lung cancer or suspected of having
lung cancer.

- To characterize the genes and proteins found to be predictive of response in order to
help elucidate the molecular biology underlying cancer chemosensitivity.

- To evaluate DNA mutations found within the lung cancer sample which may be predictive of
response or resistance to certain therapeutic agents.

OUTLINE: Patients undergo collection of tumor tissue by percutaneous fine needle aspiration,
core biopsy, thoracentesis, or during any medically indicated procedure involving removal of
lung cancer tissue. Tissue samples are analyzed by a variety of techniques, including DNA
sequencing, RNA sequencing and expression levels, protein assessment [by
immunohistochemistry, western blot, Matrix-assisted laser desorption/ionization time of
flight mass spectrometry (MALDI-MS]). The goal of these studies is to identify of gene
mutations, gene expression levels, and proteins predictive of treatment response. Blood
samples are also collected to obtain normal DNA for analysis.

After completion of study, patients will be followed until their death.

Inclusion criteria

- Diagnosis of suspected lung cancer or lung cancer

Exclusion criteria

- Inability to undergo therapy
We found this trial at
1
site
2220 Pierce Ave
Nashville, Tennessee 37232
615-936-8422
Principal Investigator: Christine Lovly, MD, PhD
Phone: 800-811-8480
Vanderbilt-Ingram Cancer Center The Vanderbilt-Ingram Cancer Center, located in Nashville, Tenn., brings together the clinical...
?
mi
from
Nashville, TN
Click here to add this to my saved trials